Epidermal growth factor receptor inhibitors in adjuvant treatment of lung cancer-the more specific, the better?

Affiliations

¹ Division of Pulmonology, Department of Internal Medicine, Medical University Graz, Graz, Austria.
² Division of Oncology, Department of Internal Medicine, Medical University Graz, Graz, Austria.

Editorial

Elisabeth Smolle et al. J Thorac Dis. 2018 Nov.

. 2018 Nov;10(Suppl 33):S3961-S3964.

doi: 10.21037/jtd.2018.09.81.

¹ Division of Pulmonology, Department of Internal Medicine, Medical University Graz, Graz, Austria.
² Division of Oncology, Department of Internal Medicine, Medical University Graz, Graz, Austria.

No abstract available

Conflict of interest statement

Conflicts of Interest: The authors have no conflicts of interest to declare.

The superstars of precision medicine-EGFR inhibitors in adjuvant treatment of lung cancer.
Xia J, Zhong WZ, Wu YL. Xia J, et al. J Thorac Dis. 2019 Jan;11(1):E11-E13. doi: 10.21037/jtd.2018.12.72. J Thorac Dis. 2019. PMID: 30863616 Free PMC article. No abstract available.

Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage II-IIIA (N1-N2) EGFR-mutant NSCLC (ADJUVANT/CTONG1104): a randomised, open-label, phase 3 study.
Zhong WZ, Wang Q, Mao WM, Xu ST, Wu L, Shen Y, Liu YY, Chen C, Cheng Y, Xu L, Wang J, Fei K, Li XF, Li J, Huang C, Liu ZD, Xu S, Chen KN, Xu SD, Liu LX, Yu P, Wang BH, Ma HT, Yan HH, Yang XN, Zhou Q, Wu YL; ADJUVANT investigators. Zhong WZ, et al. Lancet Oncol. 2018 Jan;19(1):139-148. doi: 10.1016/S1470-2045(17)30729-5. Epub 2017 Nov 21. Lancet Oncol. 2018. PMID: 29174310 Clinical Trial.

1. Zhong WZ, Wang Q, Mao WM, et al. Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage II-IIIA (N1-N2) EGFR-mutant NSCLC (ADJUVANT/CTONG1104): a randomised, open-label, phase 3 study. Lancet Oncol 2018;19:139-48. 10.1016/S1470-2045(17)30729-5 - DOI - PubMed
1. Arriagada R, Dunant A, Pignon JP, et al. Long-term results of the international adjuvant lung cancer trial evaluating adjuvant Cisplatin-based chemotherapy in resected lung cancer. J Clin Oncol 2010;28:35-42. 10.1200/JCO.2009.23.2272 - DOI - PubMed
1. Burdett S, Pignon JP, Tierney J, et al. Adjuvant chemotherapy for resected early-stage non-small cell lung cancer. Cochrane Database Syst Rev 2015;(3):CD011430. - PMC - PubMed
1. Eberhardt WE, De Ruysscher D, Weder W, et al. 2nd ESMO Consensus Conference in Lung Cancer: locally advanced stage III non-small-cell lung cancer. Ann Oncol 2015;26:1573-88. 10.1093/annonc/mdv187 - DOI - PubMed
1. Ettinger DS, Wood DE, Akerley W, et al. NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 4.2016. J Natl Compr Canc Netw 2016;14:255-64. 10.6004/jnccn.2016.0031 - DOI - PMC - PubMed